JNJ 42165279

Drug Profile

JNJ 42165279

Alternative Names: JNJ-42165279

Latest Information Update: 05 Jan 2017

Price : $50

At a glance

  • Originator Janssen-Cilag
  • Class Anxiolytics
  • Mechanism of Action Fatty acid amide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anxiety disorders

Most Recent Events

  • 27 Dec 2016 Phase-II clinical trials in Anxiety disorders in USA, Australia, Canada (PO) (NCT02432703)
  • 22 Jan 2016 Janssen suspends phase II trials in Anxiety disorders in USA, Australia, Canada, Spain, Russia, Ukraine, Romania and Moldova (NCT02498392 and NCT02432703)
  • 01 Oct 2015 Phase-II clinical trials in Anxiety disorders (Treatment-experienced) in USA (PO) (NCT02498392)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top